NCT03194932View on ClinicalTrials.gov

Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage

PHASE1CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

July 11, 2017

Primary Completion Date

October 27, 2020

Study Completion Date

June 22, 2022

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Venetoclax

Venetoclax will be given as oral tablets, which are intended to be swallowed intact and may not to be crushed or otherwise altered for administration, or as an oral suspension for patients who cannot swallow tablets.

DRUG

Cytarabine

Given intravenously (IV) or intrathecally (IT).

DRUG

Idarubicin

Given IV.

DRUG

Intrathecal Triple Therapy

Given IT.

DRUG

Azacitidine

Given IV.

Trial Locations (3)

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

38105

St. Jude Children's Research Hospital, Memphis

94304

Lucille Packard Children's Hospital Stanford University, Palo Alto

All Listed Sponsors
collaborator

Gateway for Cancer Research

OTHER

lead

St. Jude Children's Research Hospital

OTHER

NCT03194932 - Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage | Biotech Hunter | Biotech Hunter